Fig 1: Effect of the 2,4-Di-Cl-MGV-1 on NF-?B p65 (pS536) levels (measured by ELISA) in LPS- stimulated BV-2 ?cells. BV-2 ?cells were exposed to 100 ?ng/ml LPS for 24 ?h with or without 2,4-Di-Cl-MGV-1 or DS (25 ?µM each). Concentrations (µg/ml) were calculated using a standard calibration curve and are presented as Means ?± ?SD; 4 replicates in each group. ANOVA with Bonferroni’s post-hoc test was performed (p ?< ?0.001 compared to all other groups).
Fig 2: Vemurafenib inhibited mTOR and p70S6K activation in dyW-/- mice. Levels of (A) phosphorylated ERK1/2 (pT202/Y204), (B) phosphorylated STAT3 (pY705), (C) phosphorylated NF?B p65 (pS536), (D) phosphorylated JNK1/2 (pT183/Y185), (E) phosphorylated mTOR (pS2448) and (F) phosphorylated p70S6K (pT389) in protein extracts of gastrocnemius muscle from WT mice, vehicle-treated dyW-/- mice and vemurafenib-treated dyW-/- mice. One-way ANOVA with uncorrected Fisher's LSD test was performed for the data that followed the normal distribution [ERK1/2 (pT202/Y204), mTOR (pS2448) and NF?B p65 (pS536)]. Kruskal–Wallis test was performed for the data that did not follow the normal distribution [STAT3 (pY705), JNK1/2 (pT183/Y185) and p70S6K (pT389)]. All data are represented by statistical significance of mean±s.e.m. (n=10 for all groups). ns, not significant; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.
Supplier Page from Abcam for NF kappaB p65 (pS536) ELISA Kit